The management landscape for Diabetes Mellitus (both Type 1 and Type 2) has changed drastically. Innovations in the mobile health technology space have allowed patients with diabetes to have improved glycemic control with more data available to them and their providers. Clinical trials in diabetes have also improved data capture, safety and accessibility using new mobile health platforms, specifically hybrid and virtual trial technology.
This educational webinar will provide an overview of the mobile health technology space, highlighting current innovations and challenges. The discussion will be moderated by Dr. Barry Goldstein following presentations by Dr. Manasi Jaiman and Dr. Bola Oyegunwa.
Barry Goldstein, MD, PhD, FACE, Vice President & Therapeutic Area Head, Cardiovascular, Metabolic, Endocrinology & Renal, Covance
Dr. Barry J. Goldstein is a board-certified endocrinologist who is an internationally-recognized authority on diabetes mellitus. Dr. Goldstein has over 25 years of broad experience in clinical and basic R&D in Academia and Industry, serving as the PI or Co-PI on nearly 100 clinical trials. He is an elected member of the ASCI and AAP, a past associate editor of the two major journals in his specialty, DIABETES and the Journal of Clinical Endocrinology and Metabolism, and has served on many grant panels for NIH, ADA and JDRF as well as industry scientific advisory panels.
Dr. Goldstein received his combined MD/PhD degrees from the University of Rochester School of Medicine and Dentistry. He completed his postdoctoral research and clinical fellowships at the Joslin Diabetes Center and Brigham and Women’s Hospital, both of Harvard Medical School, where he also served on the medical faculty for several years.Message Presenter
Manasi Jaiman, MD, MPH, Senior Medical Director, Cardiovascular, Metabolic, Endocrinology & Renal, Covance
Dr. Manasi Jaiman has extensive clinical and academic experience in pediatric T1DM and also provides medical and scientific expertise for clinical trials and protocols in diabetes and diabetes devices. Before joining Covance, Dr. Jaiman was involved in a variety of clinical research activities including a role as a lead clinician for a major T1DM program developing a dual-chambered “bionic pancreas.”
Dr. Jaiman received an MPH in Health Systems Management from Tulane University before obtaining her MD from the Medical University of South Carolina. She completed her pediatric residency at Dartmouth-Hitchcock Medical Center and her Pediatric Endocrinology Fellowship at Massachusetts General Hospital (MGH) in Boston, Massachusetts where she continues to remain on faculty as assistant in Pediatrics.Message Presenter
Bola Oyegunwa, PhD, MBA, Vice President and Global Head of Hybrid and Virtual Trials, Covance
Dr. Bola Oyegunwa serves the biopharmaceutical industry as an experienced thought leader in developing and implementing innovative technology-enabled hybrid and virtual trial solutions. As a champion of reducing patient burden in clinical trials, he regularly engages with regulatory authorities across North America and Europe to remove regulatory barriers to the adoption of virtual clinical trials. Dr. Oyegunwa is an ex-strategy consultant and has held leadership roles in Corporate Strategy, Product Development and Innovation at leading CROs. He holds a PhD in Cellular Immunology & Microbiology, an MBA and MMB Professional Science Masters in Microbial Biotechnology, all from North Carolina State University.Message Presenter
Who Should Attend?
- Chief Medical Officer
- Chief Executive Officer
- Senior Medical Director
- Medical Director
- Clinical Development Director
- Research and Development Director
- Operational Director
- Senior Operational Director
- Clinical Director
- Senior Clinical Director
- Research Director
What You Will Learn
- Become familiar with technological advances in mobile health platforms in diabetes
- Identify challenges and gaps with current platforms and capabilities
- Understand services available for patients/sites
- Appreciate how mobile technologies can support COVID-19 issues in clinical trials
- Discuss Hybrid/Virtual trials in the clinical research space
Covance is a business segment of LabCorp, a leading global life sciences company, which provides contract research services to the drug, medical device and diagnostics, crop protection and chemical industries. Employing over 21,000 people worldwide, we are the world’s most comprehensive CRO, dedicated to improving health and improving lives.
Covance is a global leader in nonclinical safety assessment, clinical trial testing and clinical trial management services. Our unique perspectives are based on decades of scientific, medical, and regulatory expertise. We generate more safety and efficacy data to support drug approvals than any other company, supporting our clients’ complete lifecycle management.
Together with our clients, Covance transforms today’s healthcare challenges into tomorrow’s solutions. Visit us at www.covance.com.